Skip to main content

Table 2 Detailed location of PET-positive inguinal LN at primary diagnosis of anal cancer

From: Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines

Pat. No

LN No

LN station

 

Cranio-caudal distance in cm

Vessels radial distance in cm

   

LN Diameter

Saphenous junction (RTOG)

Anal verge

Lesser tuberosity (AGITG)

Lesser trochanter (BNG)

Fem.

Saph.

Skin

1

1

inferior

1.2

−1

+ 2.1

+ 2.4

+ 3

1.2

0.6

0.8

 

2

inferior

1.4

-1

+ 2.1

+ 2.4

+ 3

1.4

0.7

1.1

2

3

superomedial

1.7

0

+ 0.9

+ 1.5

+ 2.4

2.1

0.9

 

4

superomedial

1.6

−3

−0.5

0

+ 1.0

2.4

0.8

1.2

 

5

inferior

1.5

−4

−1.5

− 0.5

0

1.4

0.9

1.2

 

6

inferior

1.3

−3

−0.5

+ 0.5

+ 1.0

2.1

1.0

0.7

 

7

inferior

1.0

−1

+ 1.0

+ 1.5

+4.0

0.8

0.9

1.6

3

8

superomedial

1.0

−0.3

3.3

3.3

3.9

1.1

0.5

0.9

4

9

inferior

1.2

−5.5

−2.5

−2.5

−0,5

1.8

0.7

1.6

 

10

inferior

2.6

−3

0

0

+ 2

2.4

1.0

2.1

 

11

inferior

1.0

-3

0

0

+ 2

1.7

0.7

2.5

 

12

inferior

1.0

−2.5

+ 1.0

+ 0.5

+ 2.5

0.8

0.6

2.9

 

13

profound

2.6

0

+4

+ 3

+4.5

1.7

1.3

1.2

 

14

superolateral

2.1

+ 1.5

+ 5

+4

+ 6

2.6

0.8

 

15

superolateral

0.8

+4.5

+ 7

+ 6.0

+ 7.5

2.8

0.6

 

16

inferior

1.0

−2

+ 3

+ 1.5

+4.0

0.7

1.1

2.9

 

17

superomedial

2.3

−1.2

+ 3.6

+ 4.1

+ 5.7

1.4

1.3

1.1

 

18

profound

0.6

+ 3.3

+ 6.3

+ 7.2

+ 8.9

0.4

3.9

 

19

profound

1.0

+4.5

+ 7.5

+ 7.8

+ 9.3

0.8

4.5

 

20

profound

0.6

+ 1.3

+4.3

+4.8

+ 6.7

0.4

2.8

 

21

profound

1.0

+ 2.9

+ 5.4

+ 5.4

+ 7.3

0.6

3.0

 

22

profound

0.9

+ 3.2

+ 6.4

+ 7.3

+ 8.9

0.7

2.4

5

23

superomedial

0.9

−1.4

+ 5.5

+ 3.4

+ 5.4

0.7

0.7

2.7

6

24

superomedial

1.1

+ 1,4

+ 7.5

+ 5.1

+ 6.6

0.7

0.7

0.9

7

25

superomedial

1.4

+ 2.5

+ 7.4

+ 6.3

+ 6.4

2.5

2.8

8

26

superomedial

1.3

−1.6

+ 3,6

+ 3,6

+ 3,6

1.4

0.6

2.9

 

27

profound

1.9

−1.8

+ 3.9

+ 3.9

+ 3.7

1.3

1.0

1.6

 

28

profound

2.1

0

+4.3

+4.5

+4.4

1.1

1.5

3.1

 

29

profound

1.2

0

+ 5.2

+ 5.2

+ 5.3

1.9

1.5

2.4

 

30

superolateral

1.4

+ 2.3

+ 5.5

+ 5.4

+ 5.4

1.7

2.1

 

31

profound

1.0

+ 2.0

+ 5.3

+ 5.3

+ 5.4

0.6

5.5

9

32

superomedial

1.3

+ 2.1

+ 5.1

+ 5.6

+ 7.0

0.7

0.7

 

33

profound

1.6

+ 1.6

+ 5.6

+ 5.0

+ 6.4

0.9

0.9

10

34

inferior

1.4

−5.7

−2.6

−0.7

−0.2

2.8

0.8

1.3

 

35

inferior

1.3

−5.6

−2.6

−0.6

0

2.3

0.7

1.5

 

36

inferior

1.5

−2.8

−0.7

+ 1.3

3.2

1.3

0.8

1.3

 

37

inferior

1.2

−2.8

−0.7

+ 1.4

+ 3.3

1.4

0.8

1.5

 

38

superomedial

0.9

−1.9

+ 1.3

+ 3.4

+4.3

1.7

0.4

1.3

 

39

superolateral

1.2

− 0.6

+ 3.1

+ 5.1

+ 6

1.3

0.7

 

40

profound

1.0

+ 1.5

+ 3.9

+ 5.8

+ 6.9

0.7

0.8

 

41

profound

1.0

+ 2.5

+4.9

+ 6.8

+ 7.9

0.6

1.5

 

42

inferior

0.8

−1.9

+ 1.4

+ 3.4

+4.3

0.7

0.4

1.0

 

43

profound

1.2

−1.6

+ 2.1

+4.1

+ 5.1

0.8

1.0

3.0

 

44

superomedial

1.0

+ 1.5

+ 3.9

+ 5.9

+ 7.0

1.5

1.4

 

45

superomedial

0.9

+ 2.4

+4.9

+ 6.9

+ 7.8

1.4

1.1

 

46

profound

0.8

+ 2.4

+4.9

+ 6.9

+ 7.9

1.5

0.8

 

47

profound

0.7

+ 2.3

+4.8

+ 6.8

+ 7.8

1.3

0.3

 

48

superolateral

0.7

+ 3.4

+ 5.3

+ 7.3

+ 8.3

0.9

0.6

 

49

superolateral

0.8

+ 3.9

5.9

+ 7.8

+ 8.9

1.1

0.6

  1. LN = Lymph node, Pat. = Patient, No = number, cm = centimetre, Saph. = great saphenous vein, Fem. = femoral vessels. RTOG = Radiation Oncology Group, AGITG = Australasian Gastrointestinal Trials Group, BNG = British National Guidance. + = cranial distance, − = caudal distance. Red = LN mainly outside elective CTV.